| Literature DB >> 32728221 |
Mireille Laforge1, Carole Elbim2, Corinne Frère3, Miryana Hémadi4, Charbel Massaad1, Philippe Nuss2,5, Jean-Jacques Benoliel1,6, Chrystel Becker7.
Abstract
Entities:
Mesh:
Substances:
Year: 2020 PMID: 32728221 PMCID: PMC7388427 DOI: 10.1038/s41577-020-0407-1
Source DB: PubMed Journal: Nat Rev Immunol ISSN: 1474-1733 Impact factor: 53.106
Fig. 1SARS-CoV-2 infection can lead to neutrophilia-induced ROS release.
a | In not at-risk individuals, an excess of reactive oxygen species (ROS) is counterbalanced by an increase in antioxidant defences. b | In subjects with impaired redox balance, ROS production is not properly controlled, leading to red blood cell (RBC) membrane peroxidation, which in turn perpetuates neutrophil activation. Excessive oxidative stress might be responsible for the alveolar damage, thrombosis and RBC dysregulation seen in COVID-19. Anti-oxidants and elastase inhibitors may have therapeutic potential.